Novo Nordisk (NYSE:NVO) did something this year that usually pleases investors: it raised its full-year outlook. The shares fell anyway, with investors fixated on pricing pressure and the quality of the beat. Then, at a strategy day in London a few weeks ago, management said it aims to grow revenue through 2030 at roughly the pace of large drugmaker peers.
Founded in 1923, the Danish company built its heritage in diabetes care. Today it makes Wegovy, Ozempic and a growing line of diabetes and obesity medicines, now joined by a Wegovy pill, and it sells in around 170 countries. Whether the sell-off went too far depends on what a company promising peer-level growth is worth, and on how quickly its newest products can carry the load.
A Giant that Lost its Lead
Novo’s reach is hard to copy. It employs about 66,700 people across 80 countries, and its Wegovy franchise still leads branded obesity medicines in the US by new patient starts. The pill is the freshest proof: weekly prescriptions topped 265,000 in a single week this summer, and the company said total prescriptions had passed 5 million since launch.
But the lead isn’t what it was. CNBC reported earlier this year that Eli Lilly’s Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and Novo’s next-generation shot, CagriSema, missed its goal of proving it was not inferior to Lilly’s tirzepatide. Scale and an established franchise still protect the business. They no longer guarantee the best product. Eli Lilly is the rival that took the lead in obesity drugs. See how its stock compares with Novo’s.
Better Numbers, Smaller Ambitions
The latest quarter looked better than the headline. In the second quarter of 2026, adjusted sales rose 7% at constant exchange rates, and adjusted operating profit rose 11%. (Adjusted figures strip out one-time items.) Reported operating profit fell 16%, dragged down by a DKK 6.3 billion non-cash impairment on pipeline assets and by a year-ago rebate reversal that made last year’s quarter look bigger.
Novo then raised its 2026 outlook: adjusted sales and operating profit are now expected to land between flat and down 6% at constant exchange rates. The strategy day set the longer view: more than five multi-blockbuster launches by 2030, over DKK 150 billion in pipeline sales in 2035, and revenue growth in line with peers from 2026 to 2030. Management stressed that these are ambitions, not guidance.
Can the Pill Carry the Growth?
CNBC’s coverage of the results found investors focused on pricing pressure, the quality of the beat, and whether the pill can become big enough to matter. The quality worry has substance. Novo’s own release credits the quarter’s adjusted sales growth partly to favorable US rebate adjustments, which don’t repeat on command. The CEO also had to defend the pill’s economics as lower prices weighed on sales.
Against that, the volume is real, and launches in the UAE and the UK are adding to it. But volume only wins if prices stop falling. That risk stays standing. Want more turnaround stories from the drug industry? Browse a few healthcare stocks trying to win back investor trust.
Pricing in Plenty of Bad News
At about 11 times expected earnings, Novo costs less than most of its sector. The forward P/E (price relative to next year’s expected profit) is 10.97, as of October 6, against 18.77 for the sector and a five-year average of 27.91. In plain English, investors pay roughly $11 for each $1 of expected earnings, versus about $19 for the sector and about $28 for Novo’s own recent past. The gap has reasons. A company guiding to flat-to-down results and aiming for peer-level growth doesn’t earn its old multiple, and that five-year average reflects a market that once paid for far more. But the sector multiple is a fair yardstick for the new ambition: if Novo delivers growth like its peers, it’s priced well below them.
The catch is that forward P/E rests on estimates. If prices keep sliding, those estimates fall, and the stock looks less cheap on smaller numbers. This analysis leans on adjusted figures because reported results carry a large impairment, which also means one-time rebate benefits deserve a second glance. Hedge fund interest ticked up, with 59 funds holding the stock in the most recent quarter, up from 55 in the prior one. Short interest is just 0.83% of the float, which points to relatively limited bearish positioning.
Average Growth, Below-Average Price
Paying about 11 times expected earnings means paying far less than the sector average for a business whose outlook has stopped worsening and whose pill is still ramping. That makes the setup more interesting than the share-price slide suggests, though the discount is a fair response to a company aiming only for peer-level growth. It suits patient investors who can live with pipeline setbacks. A pill whose prescriptions stall, or prices that erode faster than volume grows, would change the picture.
READ NEXT: Top 10 AI Stocks That Will Skyrocket and 2 Stocks Trump Bought in July Are Now Down 17% to 20%. Time to Buy?
